Non-azole ergosterol biosynthesis inhibitors as antifungal drugs

References

• HOLT RJ: The imidazoles. In: Antifungal Chemotherapy. Speller DCE (Ed) John Wiley and Sons, Chichester, UK 1980 p107–147.
   Google Scholar
• RICHARDSON K, COOPER K, MARRIOTT MS, TARBIT MH, TROKE PF, WHITTLE PJ: Discovery of fluconazole, a novel antifungal agent. Rev. Infect. Dis. (1990) 12\(Suppl. 3):5267–5271.
   Google Scholar
• PETERS F, VAN DER PAS H, PROOST J: Itraconazole (R51211) a new orally active triazole derivative for the treatment of vaginal candidosis. Cu. 7ber. Res. (1986) 39:496–504.
   Google Scholar
• SEKHON AS, PADHYE AA, GARG AK, HAMIR Z: Effects of culture media on the in vitro susceptibility of selected opportunistic fungi to fluconazole and itraconazole. Chemotherapy (1992) 38:169–173.
   PubMed Web of Science ®Google Scholar
• TROICE PF, ANDREWS RJ, PYE GW, RICHARDSON K: Flu-conazole and other azoles: translation of in vitro activ-ity to in vivo and clirt1v21 efficacy. Rev. Infect. Dis. (1990) 12\(Suppl. 3):5276–5280.
   Google Scholar
• HAHN YH, AHEARN DG, WILSON LA: Comparative effi-cacy of amphotericin B, clotrimiazole and itraconazole against Aspergillus spp. An in vitro study. Myco-pathologica (1993) 123:135–140.
   Google Scholar
• MOORE L, ELLIS DH, SUPPIAH R, BYARD RW, TOOGOOD IR:Complete eradication ofAspergillusfuntigatus from the lung in an brununocompromised patient by oral itraconazole. J. Pediatr. Child Health (1993) 29:141–143.
   Google Scholar
• MARRIOTT MS: The rational design of fungal lanosterol C14 demethylase inhibitors. In: Molecular Aspects of Che-motherapy. Barowski E, Shugar D (Eds) Pergamon Press 1990 p193–204.
   Google Scholar
• EDWARDS JR, NAVIN K, MEGSON GM, SHEPHERD GL,HUGHES GD, TURNER PJ: D0870, a new triazole antifun-gal agent in vitro and in vivo laboratory evaluations. 18th International Congress of Chemotherapy, Stockholm (1993). Abstract 1504.
   Google Scholar
• MOORE CB, LAW D, DENNING DW: In vitro activity ofthe new triazole D0870 compared with amphoterkin B and itraconazole against Aspergillus spp. J. Antimicob. Chemot her. (1993) 32:831–836.
   PubMed Web of Science ®Google Scholar
• COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N. Eng. J. Med. (1994) 330:263–272.
   PubMed Web of Science ®Google Scholar
• BOREN DJ, SWINDELLS S, RINALDI MG: Fluconazole re-sistant Candida athicans. Clin. Inf. Dis. (1993) 17:1018–1021.
   PubMedGoogle Scholar
• ODDS FC: Resistance of yeasts to azole-derivative anti-fung-als. J. Antimicrob. Chemother. (1993) 31:463–471.
   PubMed Web of Science ®Google Scholar
• PYE GW, MARRIOTT MS: Inhibition of sterol C14 de-methylation by imidazole-containing antifungals. Sabouraudia (1982) 20:325–329.
   PubMedGoogle Scholar
• POLAK A: Mode of action of morpholine derivatives. Ann. N. Y. Acad. Sci. (1988) 544:221–228.
   PubMedGoogle Scholar
• STUTZ A: Synthesis and structure activity correlations within allylamine antimycotics. Ann. N. Y. Acad. Sci. (1988) 544:46–62.
   PubMedGoogle Scholar
• AGNEW WS: Squakne synthetase. Method. Enzymot (1985) 110:359–373.
   PubMedGoogle Scholar
• BERGSTROM JD, KURTZ MM, REW DJ, AMEND AM, KARICASJD, BOSTEDOR RG, BANSAL VS, DUFRESNE C, VAN MID-DLESWORTH FL: Zaragozk acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Nat. Acad. Sci. USA (1993) 90:80–84.
   PubMed Web of Science ®Google Scholar
• DAWSON MJ, FARTHING JE, MARSHALL PS, MIDDLETONRF, O'NEILL MJ, SHUTTLEWORTH A, STYLE C, TAIT RM, TAYLOR PM, WILDMAN HG, BUSS AD, LANGLEY D, HAYES MV: The squalestatins, novel inhibitors of squalene synthase produced by a species of Pboma .1 Antibiotics (1992) 45:639–647.
   Google Scholar
• HASUMI K, TACHIKAWA K, SAKAI K, MURAKAWA S, YOSHIKAWA N, ICUMAZAWA S, ENDO A: Competitive Inhibition of squalene synthetase by squalestathi I. J Antibiotics (1993) 46:689–691.
   PubMed Web of Science ®Google Scholar
• RYDER NS: Mechanism of action and biochemical selec-tivity of allylamine agents. Ann. N. Y. Acad. Sci. (1988) 544:208–220.
   PubMedGoogle Scholar
• SUTOH T, HORIE M, WATANABE H, TSUCHIYA Y, KAMEI T: Enzymatic properties of squalene epoxidase from S. cerevisiae. Biol. Pharm. Bull. (1993) 16:349–352.
   PubMed Web of Science ®Google Scholar
• STUTZ A, NUSSBAUMER P: SDZ 87-469. DrugsFuture(1989) 14:639–642.
   Google Scholar
• NUSSBAUMER P, PETRANYI G, STUTZ A: Synthesis and structure activity relationships of benzo[b]thknylally-'amine antimycotics. J. Med. Chem. (1991) 34:437–455.
   Google Scholar
• NUSSBAUMER P, DARFSTATTER G, GRASSBERGER MA, LEITNER I, MEINGASSNER JG, THIMING K, STUTZ A: Syn-thesis and structure activity relationships of phenyl-substituted benzylamine antimycotics: a novel lbenzyl benzylamine antifungal agent for systemic treatment J. Med. Chem. (1993) 36:2115–2120.
   Web of Science ®Google Scholar
• DAURIOTI A, JUNG M, MANN J, SMITH GP: Synthesis of analogues of squalene as potent antifungal agents. J. Chem. Soc. Perkin. Trans. (1993) 1:3073–3076.
   Google Scholar
• BUNTAL CJ, GRIFFIN JH: Nucleotide and deduced amino add sequences of the oxidosqualene cydase of Candida albicans . J. Am. Chem. Soc. (1992) 114:9711–9713.
   Web of Science ®Google Scholar
• BALLIANO G, GROSA G, MILLA P, VRIOLA F, CATHEL L: 3-carboxy-4-nitrophenyl-dithio-1, 1', 2-trisnorsqua-lene: a site directed inactivator of yeast oxidosquakne cyclase. Lipids (1993) 28:903–906.
   PubMedGoogle Scholar
• BALLIANO G, MILLA P, CEMTI M, VIOLA F, CARRANO L, CATHEL L: Differential inhibition of fungal oxi-dosqualene cycl2ce by 6E and 6Z isomers of 2, 3-epoxy-10-aza-10-11-dihydrosqualene. FEBS Letts. (1993) 320:203–206.
   PubMed Web of Science ®Google Scholar